9th Mar 2022 20:30
IQ-AI Ltd - Jersey-based medical services firm - Says phase one clinical trial for oral gallium maltolate is open for enrolment. Patient recruitment in the trial is underway and potential volunteers that meet the inclusion criteria have already been identified, it notes. Phase one dose escalation study is designed to determine the optimal dose of GaM that can be administered safely. It is the first-in-human clinical trial for an oral form of GaM to be used in patients with high-grade brain tumours, it adds.
Current stock price: 4.50 pence
Year-to-date change: down 45%
By Arvind Bhunjun; [email protected]
Copyright 2022 Alliance News Limited. All Rights Reserved.
Related Shares:
IQ-AI